Comparison tool
Macimorelin vs Gonadorelin side-by-side
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Comparison tool
Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.
Selected (2/4)
Share this peptide comparison
| Property | Macimorelin | Gonadorelin |
|---|---|---|
| Category | Hormonal | Hormonal |
| Also known as | Macrilen, AEZS-130 | GnRH, LHRH, Factrel |
| FDA approved | Yes | Yes |
| Clinical status | FDA approved diagnostic for adult growth hormone deficiency
| Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded.
|
| What to expect | GH deficiency diagnosis, hormone testing | Hormone stimulation, fertility, TRT support |
| How it works | Macimorelin is described as a peptidomimetic small molecule that imitates ghrelin signaling. It targets the growth hormone secretagogue receptor, also called the ghrelin receptor, on the anterior pituitary. Activation of that receptor produces a measurable growth hormone response, and blood sampling over 90 minutes helps distinguish a normal pituitary response from a blunted response in adult growth hormone deficiency evaluation. | Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output. |
| Typical dosing | Limited community data available · See research protocols | 100-500 mcg 2-3x weekly · 2-3x weekly · IV, subcutaneous, or pulsatile pump |
| Research dosing | 0.5 mg/kg oral single dose · Single diagnostic test · Oral solution, fasting | 100 mcg IV/SC for diagnostic testing · Single dose (diagnostic) or ongoing (therapeutic) · IV, subcutaneous, or pulsatile pump |
| Typical duration | Single diagnostic test | Single dose (diagnostic) or ongoing (therapeutic) |
| Administration | Oral solution, fasting | IV, subcutaneous, or pulsatile pump |
| Timing | Morning or as directed With or without food | Morning or as clinically directed With or without food |
| Evidence level | FDA Approved | FDA Approved |
| Possible side effects |
+2 more
|
+4 more
|
| Research summary | The supplied research summary describes macimorelin approval evidence as a head-to-head validation against the insulin tolerance test, a prior reference method that intentionally lowers blood glucose. In that comparison, the macimorelin test was reported to identify adult growth hormone deficiency in about 87% of affected people and to clear people without the condition in about 98% of cases. The described protocol used one oral dose, four blood draws, and no IV insulin. The same source notes QT prolongation as a caution and states that macimorelin is not validated for performance enhancement or anti-aging use despite its ghrelin-receptor activity. | The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG. |
| References | ||
| Full profile | View Details | View Details |
Save this comparison
Keep this research set handy with a free PeptiGuide account.
Save this comparison - free accountTrack your peptide journey
Turn research into a private protocol log when you are ready.
Track your peptide journeyEducational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.